Why it matters
Metastatic breast cancer remains a significant challenge, and resistance to endocrine therapy due to ESR1 mutations is a major contributor to disease progression. These mutations can significantly reduce the effectiveness of standard treatments, impacting the quality of life and prognosis for many patients. Fortunately, advancements in liquid biopsy technology now allow for non-invasive detection of ESR1 mutations through a simple blood test. This is crucial because early and accurate identification of these mutations can guide personalized treatment strategies and ultimately contribute to improved outcomes for those affected by metastatic breast cancer. By increasing awareness of ESR1 mutations and the availability of liquid biopsy testing, this project aims to empower patients and healthcare providers with the knowledge needed to make informed decisions about the most effective treatment options.
CPE’s Action and Plans
Cancer Patients Europe is committed to improving the lives of individuals with metastatic breast cancer. This CPE-led project focuses on raising awareness of ESR1 mutations and their impact on treatment resistance. An Advisory Committee of patients and experts has been established and actively supports CPE in the successful implementation of the project.
Additionally, an online survey was developed and conducted to assess current knowledge and identify information gaps among patients and healthcare providers. The results were subsequently included in a White Paper with recommendations for stakeholders. To broaden the reach of this important information, CPE also conducted a range of awareness-raising activities, including the launching of the white paper at the European Parliament.
Patient Voice
Expert Advisory Committee
- Dr. Umberto Malapelle (Italy)
- Dr. Federico Rojo Todo (Spain)
- Prof. Mike Hubank (UK)
- Prof. Dr. Ellen Copson (UK)
- Gema Rodriguez (Spain)
- Conchi Biurrun (Spain)
- Dr. Raed Aldieri (Europe)
- Dr. Arnaud Bayle (France)
Type of Action
Cancer Patients Europe Initiative
Project start date
2024
Project end date
2025
Lead Partner
Cancer Patients Europe
Focus Area
Advanced Therapy Medicinal Products (ATMPs)













